Ken Griffin Gritstone Bio, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$0.45 - $0.71 $15,165 - $23,927	33,700 Added 97.4%	68,300 $39,000
Q2 2024 Aug 14, 2024	SELL	$0.62 - $2.35 $85,994 - $325,945	-138,700 Reduced 80.03%	34,600 $21,000
Q1 2024 May 15, 2024	BUY	$1.96 - $2.9 $328,300 - $485,750	167,500 Added 2887.93%	173,300 $445,000
Q4 2023 Feb 14, 2024	SELL	$1.28 - $2.85 $896 - $1,995	-700 Reduced 10.77%	5,800 $11,000
Q3 2023 Nov 14, 2023	SELL	$1.19 - $2.26 $28,679 - $54,465	-24,100 Reduced 78.76%	6,500 $11,000
Q2 2023 Aug 14, 2023	SELL	$1.66 - $3.03 $164,008 - $299,364	-98,800 Reduced 76.35%	30,600 $59,000
Q1 2023 May 15, 2023	BUY	$2.13 - $3.74 $65,178 - $114,444	30,600 Added 30.97%	129,400 $359,000
Q4 2022 Feb 14, 2023	BUY	$2.17 - $3.92 $42,098 - $76,048	19,400 Added 24.43%	98,800 $340,000
Q3 2022 Nov 14, 2022	SELL	$2.46 - $4.75 $17,712 - $34,200	-7,200 Reduced 8.31%	79,400 $204,000

35.4M

395K

132K

Ticker GRTS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 73,006,896
Market Cap $2.19M
Description
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.